Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...

GuruFocus.com10-10

Net Product Sales: $40.8 million in Q2 2024. Sales Growth: 65% increase over Q1 2024. Bottles Dispensed: Over 37,000 bottles delivered to patients in Q2 2024. Gross to Net Discount: Improved to 44% in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474833097?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x1_VfvgnWqG0ZkQt3zIv.Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/032d7ed37797fcc20a347b9bf02a3b4c","is_english":true,"pubTime":"2024-10-10 05:56","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474833097","market":"us","top_or_hot":-1,"title":"Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...","media":"GuruFocus.com","content":"<div>\n<p>Net Product Sales: $40.8 million in Q2 2024.\nSales Growth: 65% increase over Q1 2024.\nBottles Dispensed: Over 37,000 bottles delivered to patients in Q2 2024.\nGross to Net Discount: Improved to 44% in...</p>\n\n<a href=\"https://finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-q2-215637912.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 05:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-q2-215637912.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Net Product Sales: $40.8 million in Q2 2024.\nSales Growth: 65% increase over Q1 2024.\nBottles Dispensed: Over 37,000 bottles delivered to patients in Q2 2024.\nGross to Net Discount: Improved to 44% in...</p>\n\n<a href=\"https://finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-q2-215637912.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-q2-215637912.html","article_id":"2474833097","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x1_VfvgnWqG0ZkQt3zIv.Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/032d7ed37797fcc20a347b9bf02a3b4c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474833097","pubTimestamp":1728510997,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Net Product Sales: $40.8 million in Q2 2024.Bottles Dispensed: Over 37,000 bottles delivered to patients in Q2 2024.Gross to Net Discount: Improved to 44% in Q2 2024 from 55% in Q1 2024.Operating Expenses: Approximately $74.8 million for Q2 2024.Cash and Marketable Securities: Approximately $323.6 million at the end of Q2 2024.Expected Bottles Dispensed in Q3: Approximately 41,000, a 10% increase over Q2 2024.GuruFocus has detected 5 Warning Signs with TARS.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Tarsus Pharmaceuticals Inc  is expanding its sales force and planning a consumer television campaign to further accelerate growth.The gross to net discount remains relatively high at approximately 44%, which could impact profitability.Operating expenses increased by approximately $9.5 million in Q2 2024, driven by sales and marketing costs and the expanded sales force.A: Bobak Azamian, CEO, anticipates a slight increase in gross-to-ne","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Tarsus Pharmaceuticals Inc(TARS)2024年第二季度收益看涨期权亮点：强劲的销售增长和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARS":1},"content_text":"Net Product Sales: $40.8 million in Q2 2024.\nSales Growth: 65% increase over Q1 2024.\nBottles Dispensed: Over 37,000 bottles delivered to patients in Q2 2024.\nGross to Net Discount: Improved to 44% in Q2 2024 from 55% in Q1 2024.\nNet Price per Bottle: More than $1,000.\nOperating Expenses: Approximately $74.8 million for Q2 2024.\nGross Margin: Approximately 93% for Q2 2024.\nCash and Marketable Securities: Approximately $323.6 million at the end of Q2 2024.\nExpected Bottles Dispensed in Q3: Approximately 41,000, a 10% increase over Q2 2024.\n\n\nWarning! GuruFocus has detected 5 Warning Signs with TARS.\n\nRelease Date: August 08, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nTarsus Pharmaceuticals Inc (NASDAQ:TARS) reported a significant 65% increase in sales from Q1 to Q2 2024, generating over $40 million in sales.\nThe company has achieved exceptional high-quality payer coverage, with contracts secured with major commercial and Medicare payers.\nApproximately 11,000 eye care providers (ECPs) are prescribing XDEMVY, with more than 60% prescribing it to multiple patients.\nTarsus Pharmaceuticals Inc (NASDAQ:TARS) is expanding its sales force and planning a consumer television campaign to further accelerate growth.\nThe company is advancing a robust pipeline with plans to bring three programs to the FDA by the end of the year, focusing on meibomian gland disease, Lyme disease prevention, and rosacea.\n\n Negative Points \n\nThe gross to net discount remains relatively high at approximately 44%, which could impact profitability.\nThere is an anticipated increase in the gross to net discount due to the Medicare donut hole, potentially affecting financial performance in the second half of the year.\nOperating expenses increased by approximately $9.5 million in Q2 2024, driven by sales and marketing costs and the expanded sales force.\nThe company expects a modest growth rate of approximately 10% in bottles dispensed in Q3, partly due to the summer slowdown in ECP offices.\nThere is a potential challenge in maintaining momentum as the company expands its sales force, which may temporarily disrupt operations.\n\n Q & A Highlights \nQ: Given the strong performance in the quarter, what are your thoughts around the consensus for Q3 and Q4? A: Bobak Azamian, CEO, mentioned that while they can't provide explicit guidance, the math suggests a positive outlook. Aziz Mottiwala, Chief Commercial Officer, added that Medicare coverage will start to impact later this year, with more expected in 2025, leading to a stable gross-to-net discount.\nQ: What are your expectations for long-term gross-to-net discounts as payer mix changes and coverage expands? A: Bobak Azamian, CEO, anticipates a slight increase in gross-to-net discount due to the Medicare donut hole issue, with improvements expected in 2025 to stabilize around 42%.\nQ: Regarding retreatment dynamics, which patient profiles are more likely to experience reinfestation? A: Bobak Azamian, CEO, noted it's early to determine retreatment volumes, but about 40% of patients recur at month 12 based on Phase 3 studies. Retreatment is expected to become more meaningful in 2025 as physicians gain experience.\nQ: Can you elaborate on the quarterly growth in ECPs and feedback on disease education efforts? A: Aziz Mottiwala, Chief Commercial Officer, highlighted the broad appeal of XDEMVY, with over 11,000 doctors prescribing it. The focus is on deepening prescribing habits and expanding utilization through increased sales force interactions and disease education.\nQ: How do you expect bottle growth to look in 2025 with a fully deployed sales force and DTC efforts? A: Jeffrey Farrow, CFO, expects continued quarter-over-quarter growth throughout 2025, driven by the full deployment of the sales force and the impact of direct-to-consumer campaigns.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474833097"}